Cutler Group’s Definium Therapeutics DFTX Stock Holding History

Cutler Group’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-21,100	Closed	-$2K	–	3940
2023 Q1	$2K	Sell	21,100 -39,600	-65%	-$132K	﹤0.01%	3192
2022 Q4	$2K	Sell	60,700 -9,400	-13%	-$26.1K	﹤0.01%	3722
2022 Q3	$5K	Buy	70,100 +66,767	+2,003%	+$641K	﹤0.01%	3673
2022 Q2	$2K	Sell	3,333 -1,754	-34%	-$22.2K	﹤0.01%	4313
2022 Q1	$9K	Buy	5,087 +94	+2%	+$1.63K	﹤0.01%	3707
2021 Q4	$15K	Sell	4,993 -140	-3%	-$4.47K	﹤0.01%	3358
2021 Q3	$38K	Sell	5,133 -10,800	-68%	-$467K	﹤0.01%	2751
2021 Q2	$106K	Buy	+15,933	New	+$836K	﹤0.01%	1828

Other funds holding DFTX

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

ABG

Ally Bridge Group New York $124M AUM 249.88% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Cutler Group's DFTX Position: Q1 2024 in Review

Cutler Group increased its Definium Therapeutics (DFTX) stake by 133% in Q1 2024, buying an estimated $975 and bringing the position to 300 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1868.

Cutler Group first reported a position in DFTX in Q2 2021 and has held it in 12 quarters since. The position peaked at $72K in Q3 2021. 135 funds tracked by Wall St. Rank hold DFTX as of Q1 2024.

Cutler Group held 300 shares of Definium Therapeutics worth $2K as of Q1 2024.
Cutler Group bought 171 Definium Therapeutics shares in Q1 2024, an estimated $975.
Definium Therapeutics made up ﹤0.01% of Cutler Group's portfolio in Q1 2024, its #1868 holding.
Cutler Group first reported a position in Definium Therapeutics in Q2 2021 and has held it in 12 quarters since.
Cutler Group's Definium Therapeutics position peaked at $72K in Q3 2021.
135 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2024.

Based on Cutler Group's 13F filing for Q1 2024, filed 19 Apr 2024.